Skip to content
Screener

Net Change in Cash at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
-$861M-150%
Eli Lilly logo
Eli LillyLLY
$3.67B+1,196%
Johnson & Johnson logo
Johnson & JohnsonJNJ
$1.98B-86.2%
Amgen logo
AmgenAMGN
$1.95B+349%
AbbVie logo
AbbVieABBV
$4.16B+1,293%
MoonLake Immunotherapeutics logo
MoonLake ImmunotherapeuticsMLTX
-$36.03M-140%

Other financials

Income statement

See full
Revenue-
Operating income-$36.4M-45.2%
Net income-$31.8M-51.5%
EPS (diluted)-$0.46+93.4%

Balance sheet

See full
Cash & equivalents$49.5M-40.7%
Total debt$1.8M+90.8%
Total equity$486.7M+33.4%
Total assets$504.5M+33.8%

Cash flow

See full
Operating cash flow-$23.6M-13.0%
CapEx$73.0K+462%
Free cash flow-$23.7M-13.3%

Valuation

See full
Market cap$5.96B+1,120%
Enterprise value$5.91B+1,289%

Returns & leverage

See full
Return on equity-27.3%-11.1pp
Debt / equity0.0×
Current ratio23.8×-6.3×

Where this comes from

Reported directly by Oruka Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect.

The source filing: Oruka Therapeutics, Inc.’s 10-Q, filed May 13, 2026.

Filed
May 13, 2026, 4:01 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001213900-26-055769
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Proceeds from issuance of common stock upon exercise of stock options and employee warrants1,698
Proceeds from at-the-market offering, net of commissions38,902
Net cash provided by financing activities40,600
Net increase in cash and cash equivalents2,58521,997
Cash and cash equivalents at beginning of period46,93561,575
Cash and cash equivalents at end of period$49,520$83,572
Supplemental disclosures of non-cash financing activities:
Amounts receivable related to exercise of stock options and employee warrants$68

Item 1. Financial Statements (Unaudited)

FAQ

What is Oruka Therapeutics, Inc.'s net change in cash?
Oruka Therapeutics, Inc. (ORKA) reported net change in cash of $2.59M in Q1 2026.
How has Oruka Therapeutics, Inc.'s net change in cash changed year-over-year?
Oruka Therapeutics, Inc.'s net change in cash decreased by 88.2% year-over-year, from $22M to $2.59M.
What is the long-term trend for Oruka Therapeutics, Inc.'s net change in cash?
Over 3 years (2022 to 2025), Oruka Therapeutics, Inc.'s net change in cash has grown at a 10.3% compound annual growth rate (CAGR), from -$10.91M to -$14.64M.
What does net change in cash mean?
Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.

Ask your AI about Oruka Therapeutics, Inc.'s net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude